Elegen
PrivateLast Round
Series B
May 14, 2024
Est. Valuation
$100M
Total Funding Raised
$36.21M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Elegen operates in Healthcare & Life Sciences and is based in San Carlos, California. Its latest recorded funding round was a Series B round in May 2024.
Elegen is a biotechnology company specializing in microfluidics technology that aims to revolutionize synthetic biology through genome engineering and rapid DNA synthesizer development to enhance biomedical progress and DNA sequence testing in healthcare.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elegen Comparables
Compare Elegen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ansa Biotechnologies | 91% | |
| Ribbon Biolabs | 89% | |
| Camena Bioscience | 83% |
For institutional investors. Book with your work email.
Elegen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 14, 2024 | ||||
| Grant | Sep 23, 2020 |
For institutional investors. Book with your work email.
Elegen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B |
| Digitalis Ventures | Series B |
| Triatomic Capital | Series B |
| Alix Ventures | Series B |
| ACVC Partners | Series B |
| 8VC | Series B |
| AME Cloud Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 32% month-over-month.
- Jun 20, 2026
Monthly visitors increased 47% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 30, 2026
Elegen Corporation licenses its gene synthesis and cell-free cloning patents and know-how exclusively and royalty-free to Azenta, Inc., which can provide gene synthesis products as a service worldwide while Elegen Corporation retains limited rights for internal research, development, limited manufacturing, and specified existing contracts.
For institutional investors. Book with your work email.
Elegen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Elegen's valuation, stock price, and market status.
Is Elegen a public or private company?
Elegen is a private company.
What is the current stock price of Elegen?
Elegen is a private company, so its shares have no public market price. Caplight tracks Elegen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Elegen worth (valuation)?
Elegen's valuation is estimated at $100.0M based on funding round data.
Can I buy Elegen stock?
Elegen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Elegen's last funding round?
Elegen's most recent funding round was Series B on May 14, 2024.
Who are the main investors in Elegen?
Key investors in Elegen include Triatomic Capital.
Will Elegen IPO soon?
No public IPO plans have been announced for Elegen.
How can I track Elegen secondary market activity?
Caplight tracks bids, offers, and trades in Elegen's shares on secondary markets.